Takashi Onda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takashi Onda has a total of 308 co-authors. Here are the top co-authors by number of shared publications:
Hiroyuki Yoshikawa
Ibaraki Prefectural Central Hospital, Kasama, Japan
22 shared publicationsTakahiro Kasamatsu
Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
12 shared publicationsYuji Taketani
Department of Obstetrics and Gynecology , Faculty of Medicine, University of Tokyo
11 shared publicationsToshiharu Yasugi
Department of Obstetrics and Gynecology , Faculty of Medicine, University of Tokyo 4 Department of Gynecology , Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital , Tokyo , Japan
10 shared publicationsToshiharu Kamura
Medical Care Education Research Foundation, Yanagawa Hospital, Yanagawa, Japan
9 shared publicationsKoji Matsumoto
Department of Obstetrics and Gynecology , Faculty of Medicine, University of Tokyo 3 Department of Obstetrics and Gynecology , University of Tsukuba , Ibaraki
7 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
A confirmatory trial of hysterectomy with minimal parametrectomy for stage IB1 cervical cancer involving a tumor diameter of 2 cm or less: a Japan Clinical Oncology Group study (JCOG1101)
Arimoto T, et al. J Gynecol Oncol. 2027 ;38:e8. https://doi.org/10.3802/jgo.2027.38.e8
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessA confirmatory trial of hysterectomy with minimal parametrectomy for stage IB1 cervical cancer involving a tumor diameter of 2 cm or less: a Japan Clinical Oncology Group study (JCOG1101)
Arimoto T, et al. J Gynecol Oncol. 2027 ;38:e8. https://doi.org/10.3802/jgo.2027.38.e8
- 30 May 2022
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (8) , 825-832
Current treatment status of older patients with gynecological cancers
The percentage of older patients with gynecological malignancies has recently been on the rise. Although prospective studies focusing on the treatment of older patients have been conducted for ovarian cancer, mainly in Europe, there have been scarce literature on cervical and endometrial cancers, and information on their treatment is currently lacking. One of the characteristics of older patients is that not only their performance status but also other factors, such as physical, mental and social factors, cause a large variability, and individual differences in their response to treatments. One of the major issues in the treatment of older patients is how to objectively measure these individual differences and link them to the appropriate treatment selection. In this review, clinical evidence for the guided treatment of older patients with gynecological cancer will be reviewed.
- 30 May 2022
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (8) , 825-832
Current treatment status of older patients with gynecological cancers
The percentage of older patients with gynecological malignancies has recently been on the rise. Although prospective studies focusing on the treatment of older patients have been conducted for ovarian cancer, mainly in Europe, there have been scarce literature on cervical and endometrial cancers, and information on their treatment is currently lacking. One of the characteristics of older patients is that not only their performance status but also other factors, such as physical, mental and social factors, cause a large variability, and individual differences in their response to treatments. One of the major issues in the treatment of older patients is how to objectively measure these individual differences and link them to the appropriate treatment selection. In this review, clinical evidence for the guided treatment of older patients with gynecological cancer will be reviewed.
- 25 August 2020
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 51 (2) , 205-212
Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602
Purpose: Computed tomography of the abdomen and pelvis is a useful imaging modality for identifying origin and extent of ovarian cancer before primary debulking surgery. However, the International Federation of Gynecology and Obstetrics staging for ovarian cancer is determined based on surgico-pathological findings. The purpose of this study is to determine whether computed tomography staging can be the surrogate for surgico-pathological International Federation of Gynecology and Obstetrics staging in advanced ovarian cancer undergoing neoadjuvant chemotherapy. Methods: Computed tomography staging was compared with surgico-pathological International Federation of Gynecology and Obstetrics staging in primary debulking surgery arm patients in a randomized controlled trial comparing primary debulking surgery and neoadjuvant chemotherapy (JCOG0602). The cancer of primary debulking surgery arm was identically diagnosed regarding the origin and extent with the cancer of neoadjuvant chemotherapy arm before accrual, using imaging studies (computed tomography and/or magnetic resonance imaging), cytological examination (ascites, pleural effusion or tumor contents fluid) and tumor marker (CA125 > 200 U/mL and CEA < 20 ng/mL). Institutional computed tomography staging was also compared with computed tomography staging by central review. Results: Among 149 primary debulking surgery arm patients, 147 patients who underwent primary debulking surgery immediately were analyzed. Positive predictive values and sensitivity of computed tomography staging for surgical stage III disease (extra-pelvic peritoneal disease and/or retroperitoneal lymph node metastasis) were 99%. Meanwhile, positive predictive values for the presence of small (≤2 cm) extra-pelvic peritoneal disease were low; <20% in omentum. Accuracy of institutional computed tomography staging was comparable with computed tomography staging by central review. Conclusions: Preoperative computed tomography staging in each institution can be the surrogate for surgico-pathological diagnosis in stage III disease of ovarian cancer patients undergoing neoadjuvant chemotherapy without diagnostic surgery, but reliability of diagnosis of stage IIIB disease is inadequate. Clinical trial registration: UMIN000000523(UMIN-CTR).
- 25 August 2020
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 51 (2) , 205-212
Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602
Purpose: Computed tomography of the abdomen and pelvis is a useful imaging modality for identifying origin and extent of ovarian cancer before primary debulking surgery. However, the International Federation of Gynecology and Obstetrics staging for ovarian cancer is determined based on surgico-pathological findings. The purpose of this study is to determine whether computed tomography staging can be the surrogate for surgico-pathological International Federation of Gynecology and Obstetrics staging in advanced ovarian cancer undergoing neoadjuvant chemotherapy. Methods: Computed tomography staging was compared with surgico-pathological International Federation of Gynecology and Obstetrics staging in primary debulking surgery arm patients in a randomized controlled trial comparing primary debulking surgery and neoadjuvant chemotherapy (JCOG0602). The cancer of primary debulking surgery arm was identically diagnosed regarding the origin and extent with the cancer of neoadjuvant chemotherapy arm before accrual, using imaging studies (computed tomography and/or magnetic resonance imaging), cytological examination (ascites, pleural effusion or tumor contents fluid) and tumor marker (CA125 > 200 U/mL and CEA < 20 ng/mL). Institutional computed tomography staging was also compared with computed tomography staging by central review. Results: Among 149 primary debulking surgery arm patients, 147 patients who underwent primary debulking surgery immediately were analyzed. Positive predictive values and sensitivity of computed tomography staging for surgical stage III disease (extra-pelvic peritoneal disease and/or retroperitoneal lymph node metastasis) were 99%. Meanwhile, positive predictive values for the presence of small (≤2 cm) extra-pelvic peritoneal disease were low; <20% in omentum. Accuracy of institutional computed tomography staging was comparable with computed tomography staging by central review. Conclusions: Preoperative computed tomography staging in each institution can be the surrogate for surgico-pathological diagnosis in stage III disease of ovarian cancer patients undergoing neoadjuvant chemotherapy without diagnostic surgery, but reliability of diagnosis of stage IIIB disease is inadequate. Clinical trial registration: UMIN000000523(UMIN-CTR).
- Top Cited Papers
- 1 May 2020
- Published by Elsevier in European Journal of Cancer
- Vol. 130, 114-125
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial
- 1 May 2020
- Published by Elsevier in European Journal of Cancer
- Vol. 130, 114-125
Top Cited PapersComparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial
- 24 April 2019
- Published by Springer Nature
- p. 393-405
Interval Debulking Surgery
- 1 January 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 148 (1) , 139-146
Prognostic factors and optimal therapy for stages I–II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study
- 1 January 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 148 (1) , 139-146
Prognostic factors and optimal therapy for stages I–II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study
- 3 December 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (12) , 6983-6988
Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results
Aim: This phase II study using nedaplatin evaluated the effectiveness and safely of concurrent chemoradiotherapy for locally advanced uterine cervical carcinoma. Patients and Methods: Patients met the following eligibility criteria,: International Federation of Gynecology and Obstetrics (FIGO) stage Ib, IIa, IIb with bulky tumor (≥40 mm) or pelvic lymph node swelling (≥10 mm), in FIGO stage IIIa, IIIb or IVa. Treatment adopted external radiation therapy combined with intracavitary brachyhtherapy using weekly nedaplain at 30 mg/m2 totaling five cycles. The primary endpoint was 3-year overall survival. Results: From June 2005 to May 2010, 45 eligible patients with uterine cervical carcinoma were registered. Histopathology was squamous cell carcinoma in 36 and adenocarcinoma in nine. The median follow-up period was 39 months. The 3-year overall survival rate was 73.0% (95% confidence interval=56.2-84.2%). No severe acute or late toxicities occurred. Conclusion: This phase II study showed external radiation therapy combined with intracavitary brachyhtherapy using weekly nedaplain to be effective and safe.
- 3 December 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (12) , 6983-6988
Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results
Aim: This phase II study using nedaplatin evaluated the effectiveness and safely of concurrent chemoradiotherapy for locally advanced uterine cervical carcinoma. Patients and Methods: Patients met the following eligibility criteria,: International Federation of Gynecology and Obstetrics (FIGO) stage Ib, IIa, IIb with bulky tumor (≥40 mm) or pelvic lymph node swelling (≥10 mm), in FIGO stage IIIa, IIIb or IVa. Treatment adopted external radiation therapy combined with intracavitary brachyhtherapy using weekly nedaplain at 30 mg/m2 totaling five cycles. The primary endpoint was 3-year overall survival. Results: From June 2005 to May 2010, 45 eligible patients with uterine cervical carcinoma were registered. Histopathology was squamous cell carcinoma in 36 and adenocarcinoma in nine. The median follow-up period was 39 months. The 3-year overall survival rate was 73.0% (95% confidence interval=56.2-84.2%). No severe acute or late toxicities occurred. Conclusion: This phase II study showed external radiation therapy combined with intracavitary brachyhtherapy using weekly nedaplain to be effective and safe.
- Open Access
- 19 July 2017
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 47 (10) , 986-990
Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)
To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO Stage IB, II, IIIA, IIIB, and a part of IIIC1 are eligible for the first registration before surgery. Next, those patients without evidence of para-aortic lymph node metastasis and multiple pelvic lymph node metastasis during surgery will be included in the second registration and randomized to either the pelvic lymphadenectomy alone arm or the pelvic and para-aortic lymphadenectomy arm. After the initial surgery, patients with post-operative recurrence risks receive adjuvant chemotherapy. The primary endpoint is overall survival. Secondary endpoints include relapse-free survival, short-term surgical outcomes, adverse events related to adjuvant chemotherapy and recurrence patterns. This trial has been registered at the UMIN Clinical Trials Registry [http://www.umin.ac.jp/ctr/index.htm] as UMIN000025399.
- 19 July 2017
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 47 (10) , 986-990
Open AccessPhase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)
To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO Stage IB, II, IIIA, IIIB, and a part of IIIC1 are eligible for the first registration before surgery. Next, those patients without evidence of para-aortic lymph node metastasis and multiple pelvic lymph node metastasis during surgery will be included in the second registration and randomized to either the pelvic lymphadenectomy alone arm or the pelvic and para-aortic lymphadenectomy arm. After the initial surgery, patients with post-operative recurrence risks receive adjuvant chemotherapy. The primary endpoint is overall survival. Secondary endpoints include relapse-free survival, short-term surgical outcomes, adverse events related to adjuvant chemotherapy and recurrence patterns. This trial has been registered at the UMIN Clinical Trials Registry [http://www.umin.ac.jp/ctr/index.htm] as UMIN000025399.
- Top Cited Papers
- 1 September 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 64, 22-31
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602
- 1 September 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 64, 22-31
Top Cited PapersComparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e17074
Accuracy of preoperative imaging diagnosis as a possible new staging system in advanced ovarian, tubal, and peritoneal cancer: Using data from Japan Clinical Oncology Group study JCOG0602.
E17074Background: We need a new staging system by preoperative imaging diagnosis when neoadjuvant chemotherapy (NAC) setting treatment becomes a standard treatment for advanced ovarian, tubal and peritoneal cancers. The purpose is to know whether we can accurately diagnose the origin and stage of cancer without diagnostic surgery before NAC. Methods: Preoperative institutional imaging diagnosis (IDx) for origin and tumor spread were compared with surgical or pathological findings in primary debulking surgery (PDS) in randomized controlled trial comparing between PDS and NAC arms in stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602). These cancers were diagnosed preoperatively by 1) imaging studies (CT and/or MRI), 2) cytology of ascites, pleural effusions or fluids obtained by tumor centesis, and 3) CA125 > 200 U/ml and CEA < 20 ng/ml. Accuracy of IDx to diagnose extra-pelvic peritoneal tumor (EPT) and retroperitoneal lymph node metastasis (LNM), and to distinguish between ≤ 2cm and > 2cm EPT w...
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e17074
Accuracy of preoperative imaging diagnosis as a possible new staging system in advanced ovarian, tubal, and peritoneal cancer: Using data from Japan Clinical Oncology Group study JCOG0602.
E17074Background: We need a new staging system by preoperative imaging diagnosis when neoadjuvant chemotherapy (NAC) setting treatment becomes a standard treatment for advanced ovarian, tubal and peritoneal cancers. The purpose is to know whether we can accurately diagnose the origin and stage of cancer without diagnostic surgery before NAC. Methods: Preoperative institutional imaging diagnosis (IDx) for origin and tumor spread were compared with surgical or pathological findings in primary debulking surgery (PDS) in randomized controlled trial comparing between PDS and NAC arms in stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602). These cancers were diagnosed preoperatively by 1) imaging studies (CT and/or MRI), 2) cytology of ascites, pleural effusions or fluids obtained by tumor centesis, and 3) CA125 > 200 U/ml and CEA < 20 ng/ml. Accuracy of IDx to diagnose extra-pelvic peritoneal tumor (EPT) and retroperitoneal lymph node metastasis (LNM), and to distinguish between ≤ 2cm and > 2cm EPT w...